drugset

drugset / Trial / NCT03550209

Fatty Acid Supplementation in Children With ASD

NCT03550209 ↗

Phase 2 Completed 72 enrolled Sarah Keim National Center for Complementary and Integrative Health (NCCIH) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to examine how fatty acid supplementation alters biological signatures in children with ASD

Timeline

Start: 2018-06-28
Primary completion: 2020-01-10
Completion: 2020-01-10

Publications

Keim SA, Jude A, Smith K, Khan AQ, Coury DL, Rausch J, Udaipuria S, Norris M, Bartram LR, Narayanan AR, Rogers LK. Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder. J Autism Dev Disord. 2022 Dec;52(12):5342-5355. doi: 10.1007/s10803-021-05396-9. Epub 2022 Jan 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LCPUFA Oil Supplement	Other / unclassified	25 mg/kg	Oral
Subject	LCPUFA Oil Supplement	Other / unclassified	50 mg/kg	Oral
Subject	LCPUFA Oil Supplement	Other / unclassified	75 mg/kg	Oral

Indications